OpGen Provides Business Update and Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2020

NEXT STORY
AnHeart Therapeutics Announces License Agreement with NewG Lab for Taletrectinib Rights in Korea
PREV STORY
Manuscript Describes How TLC’s Inhalable Liposomal Hydroxychloroquine May Provide Clinical Benefit and Serve as Potential Treatment for COVID-19
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study

author_avatar
NASDAQ Market News

Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Advaxis Stockholders Vote “FOR” Proposed Merger with Biosight

author_avatar
NASDAQ Market News

ContraFect Appoints Lisa Ricciardi as Chief Operating Officer

YONKERS, N.Y., Oct. 05, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company ...

author_avatar
NASDAQ Market News